Harsanyi Zsolt 4

What Happened

• Zsolt Harsanyi, Chairman and director of Emergent BioSolutions (EBS), received equity awards on April 30, 2026: 25,344 restricted stock units (RSUs) and 11,296 derivative securities (stock options). Both awards were granted as part of routine board and committee compensation and show $0 cash paid at grant (standard for awards).
• The RSUs (25,344) represent rights to receive one share per RSU upon vesting. The 11,296 derivative items are stock options (each option entitles the holder to buy one share upon vesting at the option exercise price). The filing records the acquisition price as $0.00 for the grants (grant value not shown in the excerpt).

Key Details

• Transaction date: 2026-04-30; Form 4 filed 2026-05-04 (timely under the two-business-day rule).
• Price: $0.00 listed for the award grants (standard for RSU/option grants); exercise price for the options is not specified in the provided excerpt.
• Vesting: Both the RSUs and options vest on the day prior to the one-year anniversary of the grant (the “Annual Grant Vesting Date”), contingent on Harsanyi remaining a board member through that date (see footnotes F1–F2).
• How option grant size was set: Number of options was calculated by converting 25% of director compensation into option counts using a Black‑Scholes per‑option value (per footnote F3).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed on May 4, 2026 for a 4/30/2026 grant — appears timely.

Context

• These are routine, annual equity awards for non-employee directors used to compensate board service. RSUs pay out shares at vesting; options give the right to buy shares at a set exercise price once vested.
• Such awards are common and reflect compensation, not an open‑market purchase or sale; they do not by themselves indicate the insider’s view of the company’s near‑term stock prospects.